• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

颅底脊索瘤的预后因素:一项系统文献综述与荟萃分析

Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.

作者信息

Zou Ming-Xiang, Lv Guo-Hua, Zhang Qian-Shi, Wang Shao-Fu, Li Jing, Wang Xiao-Bin

机构信息

Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

出版信息

World Neurosurg. 2018 Jan;109:307-327. doi: 10.1016/j.wneu.2017.10.010. Epub 2017 Oct 16.

DOI:10.1016/j.wneu.2017.10.010
PMID:29045855
Abstract

OBJECTIVE

Currently, there are a lack of reviews assessing the complete range of prognostic factors in skull base chordoma (SBC). This study aimed to systematically review the published literature on prognostic factors in SBC and establish pooled hazard ratios (HRs) of such factors.

METHODS

MEDLINE and Embase searches (inception to April 4, 2017) were conducted. Two reviewers independently selected papers involving SBC prognostic factors, and studied them for methodologic quality and valuable factors. Pooled HRs and 95% confidence intervals (CIs) were calculated. The main end points determined were progression-free survival (PFS) and overall survival (OS).

RESULTS

Twenty-two studies with 1754 subjects were included in this systematic review. However, only 18 of the studies provided sufficient data for quantitative synthesis. Preoperative visual deficit (pooled HR, 2.77; 95% CI, 1.57-4.89 for PFS), older patient age (pooled HR, 1.03; 95% CI, 1.1-1.05 for PFS; pooled HR, 1.03; 95% CI, 1.2-1.04 for OS), and nontotal or intralesional tumor resection (pooled HR, 2.01; 95% CI, 1.54-2.62 for PFS; pooled HR, 5.16; 95% CI, 2.27-11.70 for OS) were negative predictors of survival outcomes. However, adjunctive radiotherapy (pooled HR, 0.30; 95% CI, 0.16-0.56) and chondroid chordoma type (pooled HR, 0.5; 95% CI, 0.36-0.69) portended a favorable PFS. In addition, several prognostic biomarkers were promising.

CONCLUSIONS

This study demonstrated that several clinicopathologic or molecular parameters are associated with survival up to tumor progression or mortality in SBC patients. However, further methodologically high-quality reports are still required to clarify the effects of these factors.

摘要

目的

目前,缺乏对颅底脊索瘤(SBC)所有预后因素的评估综述。本研究旨在系统回顾已发表的关于SBC预后因素的文献,并确定这些因素的合并风险比(HRs)。

方法

进行了MEDLINE和Embase检索(起始至2017年4月4日)。两名审阅者独立挑选涉及SBC预后因素的论文,并研究其方法学质量和有价值的因素。计算合并HRs和95%置信区间(CIs)。确定的主要终点为无进展生存期(PFS)和总生存期(OS)。

结果

本系统综述纳入了22项研究,共1754名受试者。然而,只有18项研究提供了足够的数据用于定量综合分析。术前视力障碍(PFS的合并HR为2.77;95%CI为1.57 - 4.89)、患者年龄较大(PFS的合并HR为1.03;95%CI为1.1 - 1.05;OS的合并HR为1.03;95%CI为1.2 - 1.04)以及肿瘤未全切除或瘤内切除(PFS的合并HR为2.01;95%CI为1.54 - 2.62;OS的合并HR为5.16;95%CI为2.27 - 11.70)是生存结局的负性预测因素。然而,辅助放疗(合并HR为0.30;95%CI为0.16 - 0.56)和软骨样脊索瘤类型(合并HR为0.5;95%CI为0.36 - 0.69)预示着较好的PFS。此外,一些预后生物标志物很有前景。

结论

本研究表明,一些临床病理或分子参数与SBC患者直至肿瘤进展或死亡的生存期相关。然而,仍需要进一步的方法学高质量报告来阐明这些因素的影响。

相似文献

1
Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.颅底脊索瘤的预后因素:一项系统文献综述与荟萃分析
World Neurosurg. 2018 Jan;109:307-327. doi: 10.1016/j.wneu.2017.10.010. Epub 2017 Oct 16.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.治疗胶质母细胞瘤进展或复发的选择:网络荟萃分析。
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.右雷佐生预防或减少接受蒽环类抗生素治疗的癌症成人和儿童的心脏毒性。
Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2.
8
Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.拉莫三嗪与卡马西平单药治疗癫痫的疗效比较:个体参与者数据回顾
Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD001031. doi: 10.1002/14651858.CD001031.pub4.
9
Prognostic factors for return to work in breast cancer survivors.乳腺癌幸存者恢复工作的预后因素。
Cochrane Database Syst Rev. 2025 May 7;5(5):CD015124. doi: 10.1002/14651858.CD015124.pub2.
10
Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.阿昔替尼、卡博替尼、依维莫司、纳武利尤单抗、舒尼替尼和最佳支持治疗用于既往治疗的肾细胞癌:系统评价和经济评估。
Health Technol Assess. 2018 Jan;22(6):1-278. doi: 10.3310/hta22060.

引用本文的文献

1
Intrasellar chordoma masquerading as a pituitary neuroendocrine tumor: Illustrative case.伪装成垂体神经内分泌肿瘤的鞍内脊索瘤:病例说明
Surg Neurol Int. 2024 May 10;15:159. doi: 10.25259/SNI_116_2024. eCollection 2024.
2
The critical roles of lnc-GLYATL2-2/PD-L1 axis in immune microenvironment and the clinical value of intracranial chordomas.lnc-GLYATL2-2/PD-L1轴在免疫微环境中的关键作用及颅内脊索瘤的临床价值
Am J Cancer Res. 2023 Dec 15;13(12):6313-6332. eCollection 2023.
3
Craniovertebral Junction Instability after Oncological Resection: A Narrative Review.
肿瘤切除术后颅颈交界区不稳定:一项叙述性综述
Diagnostics (Basel). 2023 Apr 21;13(8):1502. doi: 10.3390/diagnostics13081502.
4
Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients.小儿颅底脊索瘤的手术和质子放射治疗:204 例患者的长期临床结果。
Neuro Oncol. 2023 Sep 5;25(9):1686-1697. doi: 10.1093/neuonc/noad068.
5
efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts.CDK4/6抑制剂帕博西尼和PLK1抑制剂沃拉替尼在人脊索瘤异种移植模型中的疗效评估
Front Oncol. 2022 Nov 25;12:960720. doi: 10.3389/fonc.2022.960720. eCollection 2022.
6
High systemic inflammation score is associated with adverse survival in skull base chordoma.全身炎症评分高与颅底脊索瘤的不良生存相关。
Front Oncol. 2022 Oct 14;12:1046093. doi: 10.3389/fonc.2022.1046093. eCollection 2022.
7
Mayo Clinic Clival Chordoma Case Series: Impact of Endoscopic Training on Clinical Care.梅奥诊所斜坡脊索瘤病例系列:内镜培训对临床护理的影响。
Cancers (Basel). 2022 Oct 18;14(20):5104. doi: 10.3390/cancers14205104.
8
A correlation analysis of sacrococcygeal chordoma imaging and clinical characteristics with the prognostic factors.骶尾部脊索瘤影像学及临床特征与预后因素的相关性分析
Front Oncol. 2022 Sep 26;12:1012918. doi: 10.3389/fonc.2022.1012918. eCollection 2022.
9
Differences in stromal component of chordoma are associated with contrast enhancement in MRI and differential gene expression in RNA sequencing.脊索瘤基质成分的差异与 MRI 中的对比增强以及 RNA 测序中的差异基因表达有关。
Sci Rep. 2022 Oct 3;12(1):16504. doi: 10.1038/s41598-022-20787-3.
10
Mediastinal extraosseous chordoma in a teenager: Diagnosis by ultrasound-guided percutaneous biopsy.青少年纵隔骨外脊索瘤:经超声引导下经皮穿刺活检确诊
Radiol Case Rep. 2022 Aug 10;17(10):3859-3862. doi: 10.1016/j.radcr.2022.07.085. eCollection 2022 Oct.